Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTX-COVAC: Humoral Response to COVID-19 Vaccination After Rituximab in Rheumatoid Arthritis
2021-000710-42Phase 4Completed
- Sponsor
- Sint Maartenskliniek
- Start
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of elasomeran and ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19) and rheumatoid arthritis (RA) (2 arms), sponsored by Sint Maartenskliniek. Primary endpoint: Total immunoglobulin titre against COVID-19 (primary). Started Mar 2021; status: completed.
02
Drugs
elasomeranChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2021-000710-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000710-42.